Kiniksa Pharmaceuticals, Ltd. (KNSA) financial statements (2022 and earlier)

Company profile

Business Address CLARENDON HOUSE
HAMILTON, HM11
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments182,201323,482233,380307,304
Cash and cash equivalents122,470114,03846,92871,976
Short-term investments59,731209,444186,452235,328
Restricted cash and investments 210  
Receivables3,985   
Inventory, net of allowances, customer advances and progress billings3,675   
Inventory3,675   
Other undisclosed current assets6,5859,5578,2476,446
Total current assets:196,446333,249241,627313,750
Noncurrent Assets
Operating lease, right-of-use asset5,5506,5661,927
Property, plant and equipment2,8344,0516,3986,356
Intangible assets, net (including goodwill)19,250   
Intangible assets, net (excluding goodwill)19,250   
Restricted cash and investments  210210
Deferred costs   433
Deferred income tax assets 104,372
Other noncurrent assets8,7205,588  
Deferred tax assets, net1,216
Total noncurrent assets:36,35416,21512,9078,215
TOTAL ASSETS:232,800349,464254,534321,965
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities39,89929,70226,10827,336
Accounts payable1,8685035,69310,918
Accrued liabilities38,03129,19920,41516,418
Debt  1,697 
Other liabilities1,5443725218
Other undisclosed current liabilities3,3812,107 15,000
Total current liabilities:44,82431,84627,83042,554
Noncurrent Liabilities
Long-term debt and lease obligation2,6694,878955 
Operating lease, liability2,6694,878955
Liabilities, other than long-term debt270805326144
Accounts payable and accrued liabilities   144
Other liabilities270805326 
Total noncurrent liabilities:2,9395,6831,281144
Total liabilities:47,76337,52929,11142,698
Stockholders' equity
Stockholders' equity attributable to parent, including:185,037311,935225,423279,267
Additional paid in capital860,482829,424581,467473,483
Accumulated other comprehensive income (loss)(66)(34)33(4)
Accumulated deficit(675,397)(517,473)(356,092)(194,225)
Other undisclosed stockholders' equity attributable to parent18181513
Total stockholders' equity:185,037311,935225,423279,267
TOTAL LIABILITIES AND EQUITY:232,800349,464254,534321,965

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues38,544   
Cost of revenue
(Cost of Goods and Services Sold)
(9,100)   
Gross profit:29,444   
Operating expenses(186,080)(157,363)(169,963)(108,160)
Operating loss:(156,636)(157,363)(169,963)(108,160)
Nonoperating income
(Investment Income, Nonoperating)
971,1346,0494,719
Loss from continuing operations before income taxes:(156,539)(156,229)(163,914)(103,441)
Income tax expense (benefit)(1,385)(5,152)2,047214
Net loss available to common stockholders, diluted:(157,924)(161,381)(161,867)(103,227)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(157,924)(161,381)(161,867)(103,227)
Comprehensive loss:(157,924)(161,381)(161,867)(103,227)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(32)(67)37(4)
Comprehensive loss, net of tax, attributable to parent:(157,956)(161,448)(161,830)(103,231)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: